Summary

• Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases.
• Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy.
• LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
• Also, LX2006’s early Phase 1/2 data were promising. The main caveat is that their dataset is small, and the subsequent pivotal study is open-label.
• I feel LXEO’s progress on LX2006 is quite promising. And they should have enough financing to reach LX2006’s 2027 readout, which is why I’m bullish.

Lexeo Therapeutics, Inc. (LXEO) is a clinical-stage genetic medicine company developing one-time AAV-based therapies for rare hereditary cardiovascular diseases. LX2006 leads LXEO’s pipeline for Friedreich's ataxia cardiomyopathy and LX2020 for PKP2-associated arrhythmogenic cardiomyopathy. LX2006 has positive results in Phase 1/2, with evidence

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.